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Abstract
Background: Many SNPs have been identified in genes regulating LDL-C metabolism, but whether their influence
is similar in subjects from different ethnicities is unclear. Effect of 4 such SNPs on LDL-C and coronary heart disease
(CHD) was examined in Pakistani subjects and was compared with middle aged UK men from Northwick Park Heart
Study II (NPHSII).
Methods: One thousand nine hundred sixty-five (1770 non CHD, 195 CHD) UK and 623 (219 non CHD, 404 CHD)
Pakistani subjects were enrolled in the study. The SNPs SORT1 rs646776, APOB rs1042031 and APOE rs429358, rs7412
were genotyped by TaqMan/KASPar technique and their gene score was calculated. LDL-C was calculated by
Friedewald equation, results were analyzed using SPSS.
Results: Allele frequencies were significantly different (p = <0.05) between UK and Pakistani subjects. However,
the SNPs were associated with LDL-C in both groups. In UK non CHD, UK CHD, Pakistani non CHD and Pakistani
CHD respectively, for rs646776, per risk allele increase in LDL-C(mmol/l) was 0.18(0.04), 0.06(0.11), 0.15(0.04) and
0.27(0.06) respectively. For rs1042031, per risk allele increase in LDL-C in four groups was 0.11(0.04), 0.04(0.14),
0.15(0.06) and 0.25(0.09) respectively. For APOE genotypes, compared to Ɛ3, each Ɛ2 decreased LDL-C by 0.11(0.06),
0.07(0.15), 0.20(0.08) and 0.38(0.09), while each Ɛ4 increased LDL-C by 0.43(0.06), 0.39(0.21), 0.19(0.11) and
0.39(0.14) respectively. Overall gene score explained a considerable proportion of sample variance in four
groups (3.8 %, 1.26 % 13.7 % and 12.3 %). Gene score in both non-CHD groups was significantly lower than
CHD subjects.
Conclusions: The SNPs show a dose response association with LDL-C levels and risk of CHD in both populations.
Keywords: LDL-C, SORT1, APOB, APOE, Gene score
* Correspondence: saleemullahshahid@hotmail.com
1Department of Microbiology and Molecular Genetics, University of the
Punjab, Lahore, Pakistan
Full list of author information is available at the end of the article
© 2016 Shahid et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shahid et al. Lipids in Health and Disease  (2016) 15:83 
DOI 10.1186/s12944-016-0253-0
Background
Coronary heart disease is the leading cause of death in
adults all over the world [1, 2]. The prevalence and mor-
tality rate varies in different ethnic groups and people
from Indian subcontinent are at greater risk of develop-
ing CHD [3, 4]. In Pakistani population, it is estimated
that more than 30 % of the people above 45 years of age
are affected by CHD [5]. The risk of developing CHD is
influenced by both environmental (diet, smoking, lack of
exercise) and genetic factors. Identification of common
variants in the genese regulating biochemical pathways
involved in pathogenesis of the disease may give valuable
information.[6]. Blood lipid levels are key modifiable risk
factors for CHD and other cardiovascular diseases. Low
density lipoprotein cholesterol (LDL-C) is an independent
CHD risk factor and LDL-C lowering drugs reduce CHD
risk [7, 8]. The biochemical and genetic basis of elevation
in blood lipids is not fully understood, but their heritabil-
ity has been estimated to be at least 50 % [9].
Single nucleotide polymorphisms (SNPs) can be used
to examine whether a genetic biomarker is causally
linked to a disease risk or not [1]. Most of the SNPs in
the genes regulating blood lipids are inherited independ-
ently and affect lipid levels quantitatively [10]. In con-
trast to a large body of evidence available in Caucasians,
data on the genetic regulation of lipids in Pakistani
population is limited [11]. The allele frequencies of SNPs
may show interethnic variations due to different linkage
disequilibrium (LD) patterns, genetic drift, gene flow,
mutation or admixture. Risk allele frequencies of some
SNPs may be more prevalent in specific ethnic groups,
or their effects may be modified due to environment or
life style changes [12, 13]. This in turn may generate var-
iations in disease outcomes across ethnicities [14]. Stud-
ies in non-European people will help to evaluate the true
relevance of findings in European people [15, 16]. The
APOE polymorphisms rs429385 and rs7412 result in
three major isoforms of the protein named E2, E3 and
E4. Studies have shown that presence of Ɛ4 allele in-
creases concentration of blood lipids particularly LDL-C,
while Ɛ2 is LDL-C lowering allele when compared to Ɛ3
[4]. Similarly the effects of SNPs in APOB and SORT1 on
LDL-C have been shown by many researchers [17–21].
While there are a large number of studies showing the ef-
fect of SNPs in SORTI, APOB and APOE genes with LDL-
C levels, their effect needs to be examined and replicated
in diverse ethnicities. In this study, we examined the effect
of four SNPs on serum LDL-C concentration and CHD.
These SNPs are in the genes for SORT1 (rs646776), APOB
(rs1042031) and APOE (rs429358, rs7412).
The study comprised of two cohorts, one from UK
and the other from Pakistan. The objectives of the study
were (1) to compare the allele frequencies of the selected
SNPs individually and in the form of a combined gene
score between UK and Pakistani subjects (2) determin-
ing to what extent the SNPs are affecting LDL-C; (3)
examining the association of these SNPs with CHD in
both populations.
Methods
Recruitment of subjects
The Pakistani group consisted of 404 CHD cases col-
lected from hospitals in Lahore covering the whole of
the province of Punjab, Pakistan. All subjects were Paki-
stani and ethnicity was self described by the subject or if
both of the grandparents were Pakistani. CHD cases
were diagnosed using ECG, cardiac echo, radiologic and
troponine T/I data by the cardiologist. All cases were
newly diagnosed and were not taking any lipid lowering
or anti-hypertensive drugs. Non CHD controls were eth-
nicity matched healthy individuals without any history of
cardiovascular disease and were recruited from general
population. The exclusion criteria for CHD cases was
the co-existence of any other chronic disease like liver
or kidney disease, cancer or any ongoing acute infection.
The CHD subjects with obesity were also excluded from
the study. In case of controls, the subjects having a fam-
ily history of early CHD and the obese subjects were ex-
cluded. All the subjects were pre-screened for the
presence of hepatitis B virus, hepatitis C virus and hu-
man immune deficiency virus before starting biochem-
ical and genetic analysis. Seropositive subjects were
excluded from the study. The subjects gave a written in-
formed consent and filled in a detailed questionnaire.
The Caucasian samples were from the 2nd Northwick
Park Heart Study (NPHSII) described elsewhere [22].
Briefly, NPHSII is a prospective study comprising of
middle-aged (50–64 yr) healthy UK men (n = 3052)
started in 1989. These Subjects were recruited from 9
UK general practices and were followed for a median of
13.5 years for CHD events. The subjects who developed
CHD during the follow up period were reffered as CHD
while those who remained CHD free were referred as
non-CHD. The CHD cases were defined as fatal or non-
fatal myocardial infarction or evidence of CHD such as
needing angioplasty [23]. For this analysis, only subjects
with complete information for all four SNPs were in-
cluded and the characteristics of this group did not dif-
fer significantly from the whole sample set (data not
shown).
Statement of human and animal rights
All procedures followed were in accordance with the
ethical standards of the responsible committee on hu-
man experimentation (institutional and national) and
with the Helsinki Declaration of 1975, revised in 2008.
An ethical approval was obtained from the institutional
ethical committee for Pakistani samples (PU/27/3-09)
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and national research ethics service Committee, London
Central for UK samples via reference number 14/Lo/
1412.
Statement of informed consent
Informed consent was obtained from all patients for be-
ing included in the study.
Biochemical analysis and DNA extraction
The LDL-C was determined using Friedewald equation
in NPHSII [24] and Pakistani samples. DNA was ex-
tracted by the salting out method in NPHSII samples. In
Pakistani samples, the DNA was extracted with the help
of genomic DNA purification kit (Wizard®, USA) using
standard protocol. DNA was quantified by nano drop
ND-8000 (Labtech, UK).
Genotyping
For genotyping, samples were first aliquoted into 384
well plates by a robotic liquid handling system, (Biomerk
FX, Beckman Coulter). Two florescence based allelic dis-
crimination techniques, TaqMan and KASPar, were used
for genotyping the SNPs.
TaqMan technique
The SNPs rs646776, rs1042031 and rs429358 were geno-
typed by TaqMan technique (Applied Biosystems). A re-
action mixture was prepared for 384 wells plate.The
reaction mixture consisted of, 468 μl TaqMan master
mix, 23 μl of SNP assay and 410 μl Sigma water. Taq-
Man master mix consisted of optimized concentrations
of a special Taq polymerase enzyme, MgCl2, DNTPs,
ROX high and Taq buffer. The SNP assay was specific
for each SNP and consisted of allele specific primers
and probes. The thermal cycler program consisted of a
first step at 50 °C for 2 minutes, then initial denatur-
ation/enzyme activation at 95 °C for 10 minutes. This
was followed by 40 amplification cycles, each amplifica-
tion cycle consisted of denaturation at 95 °C for 15 sec-
onds and annealing/extension at 60 °C for 1 min.
KASPar technique
The SNP rs7412 was genotyped by KASPar (KBios-
ciences Competitive Allele Specific PCR) technique. The
assay mixture for 384 well plate consisted of 900 μl
KASPar master mix, 900 μl Sigma water and 26.4 μl of
SNP assay. The touchdown thermal cycler program used
for KASPar technique consisted of an initial denatur-
ation at 94 °C for 15 minutes, then 10 cycles consisting
of 94 °C for 20 sec and annealing/extension temperature
reduced from 65 °C to 57 °C lowered by 0.8 °C per cycle.
The final round consisted of 26 amplification cycles each
amplification cycle consisted of 94 °C for 20 sec and an-
nealing/extension at 57 °C for 60 sec.
After completion of PCR, the results were analysed
by florescence resonance energy transmission (FRET)
based instrument, ABI PRISM 7900HT (Applied Bio-
systems). The genotypes were called using sequence de-
tection software (SDS) version 2.0. The genotypes were
also confirmed randomly by conventional direct DNA
sequencing (source biosciences, UK) to check the accur-
acy of techniques and the results were always the same.
Statistical analysis
The results were analysed using statistical package for
social sciences (SPSS), IBM version 22.0. The continuous
variables like LDL-C and gene score were compared be-
tween groups by independent sample t test. Hardy
Weinberg equilibrium was assessed by a chi squared
goodness of fit test. The allele frequencies were com-
pared between different groups by chi squared test. The
association of SNPs with LDL-C was estimated by linear
regression. The mean LDL-C values against each geno-
type were calculated by ANOVA. The effect size (β ef-
fect) per risk allele is the increase in LDL-C for each
additional risk allele held and was calculated by linear
regression, denoted by β along with standard error (Se).
Differences in regression slope between groups were
tested by fitting an interaction term in the regression
model. The relationship between gene score, frequency
of individuals with a particular gene score and LDL-C
was plotted using an excel spread sheet. For all the tests,
a p-value < 0.05 was considered statistically significant
cut-off.
Calculation of gene score
To combine the information of these four SNPs on
LDL-C, an unweighted gene score and a gene score
weighted for published effect size on LDL-C in European
subjects was calculated. The unweighted gene score was
calculated by summing up the number of risk alleles at
all the four loci. For the weighted score, the number of
risk alleles at that locus was multiplied by the published
effect size for the association with LDL-C before sum-
ming [25, 26].
Results
The baseline characters differed between CHD and non
CHD subjects in both study groups. The CHD subjects
had higher LDL-C concentration, a higher proportion
had hypertension and diabetes mellitus and smoking rate
was also higher than non CHD subjects. Body mass
index (BMI) was significantly higher in NPHSII CHD
than non CHD. In Pakistani samples, BMI did not sig-
nificantly differ between CHD and non CHD subjects.
These features were also compared between NPHSII and
Pakistani groups. In NPHSII, the proportion of subjects
with hypertension and those who were smokers and the
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mean LDL-C level were significantly higher whereas the
proportion of diabetes was lower than in the Pakistani
subjects (Table 1).
All the SNPs gave > 95 % genotyping call rates. Hardy
Weinberg equilibrium values for both groups are shown
(Additional file 1: Table S1). For all the SNPS, risk allele
frequencies (RAFs) were significantly different (p < 0.05)
between the NPHSII and Pakistani groups. The RAF of
rs1042031 was lower while those for rs646776, rs429358
and rs412 were higher in NPHSII subjects than Pakistani
subjects. In Pakistani group, the the RAF of rs1042031
was significantly higher in the CHD than non CHD
(0.92 vs 0.87, p = 0.007), while those for rs646776,
rs429358 and rs412, the RAFs did not not significantly
differ between CHD and non CHD groups. In NPHSII
samples, the RAFs did not differ significantly between
CHD and non CHD for either of the SNPs studied
(Additional file 2: Table S2).
Effect of SNPs on LDL-C levels
The SNPs were associated with LDL-C in both study
groups. The risk alleles of all the four SNPs increased
LDL-C quantitatively. The distribution of LDL-C along 3
different genotypes of the SNP, the effect size of risk al-
lele of each SNP (β) the proportion of sample variance
(R2), and p values are given in Table 2. For rs646776, the
common allele (A) was the risk allele and β in non CHD
subjects from both groups was comparable but a higher
value was observed in Pakistani CHD subjects. Similarly
for rs1042031, the effect size in Pakistani CHD was
higher than NPHSII and Pakistani non CHD. For the
APOE polymorphisms, rs429358 and rs7412, isoforms
Ɛ2, Ɛ3 and Ɛ4 were examined separately. When com-
pared with Ɛ3, Ɛ2 lowered LDL-C while Ɛ4 raised LDL-
C in all the study groups. Overall the effect size was
significant for all the SNPs in all subjects except NPHSII
CHD group. The effect sizes were almost same in
healthy UK and Pakistani people but a bigger effect was
always observed in Pakistani CHD group (Table 2).
Gene score analysis
Individually, the risk allele frequencies were not signifi-
cantly higher in CHD than non-CHD except rs1042031
in Pakistani samples. However, collectively the un-
weighted gene score of the four SNPs was significantly
higher in CHD than non CHD of both study groups
(Table 3, Additional file 3: Figure S1). The effect of gene
score on LDL-C was also observed. The effect size of
unweighted gene score in NPHSII non CHD was similar
to the Pakistani non CHD (0.19 vs 0.17, p = 0.82). How-
ever, a bigger effect in Pakistani CHD cases (0.29 ± 0.04)
was observed than other groups (Table 4). Mean LDL-C
values in groups of subjects with different number of
LDL-C raising alleles (unweighted gene score) in the
NPHSII and Pakistani group is shown in Figs. 1 and 2
respectively.
To observe the impact of increasing number of risk al-
leles in groups with different baseline LDL-C values, we
grouped the individuals according to the number of risk
alleles they had. The difference in mean LDL-C levels
between those with 6 risk alleles versus those having 2
risk alleles was similar in NPHSII non CHD, Pakistani
non CHD and Pakistani CHD group (Additional file 4:
Table S3).
Discussion
In this study, we have analyzed the effect of four SNPs
in three genes that were known to have their influence
on LDL-C metabolism. We have examined their effect in
a Pakistani CHD case control study and compared it
Table 1 Baseline characteristics of NPHSII compared with the Pakistani cohort
Variable NPHSII samples Pakistani Samples P* P**
Non CHD CHD p-value Non CHD CHD p-value
Sample number 1770 195 219 404
Age (years) 55.9 ± 3.4 56.7 ± 3.5 0.0002 56 ± 10.5 59.1 ± 12.6 0.002 0.87 0.01
Sex
Males (n) 1770 195 119 238 0.27 - -
Females (n) 0 0 100 166
Diabetes (%) 2.1 5.6 0.006 13.6 64.6 5.1×10-34 2.7x10-19 5.3x10-42
Hypertension (%) 52.6 61.0 0.03 16.4 62.1 8.9x10-28 5.5x10-24 0.80
Smoking (%) 27.8 39.5 0.001 10.5 29.5 7.3x10-08 3.5x10-08 0.01
LDL-C (mmol/l) 3.05 ± 1.01 3.36 ± 0.94 0.00007 2.19 ± 0.44 2.74 ± 0.75 6.5x10-22 1.8x10-34 3.5x10-17
BMI 26.4 ± 3.5 27 ± 3.5 0.019 21.46 ± 9.11 22.46 ± 6.75 0.104
NPHSII Northwick Park heart study II, CHD coronary heart disease, P* NPHSII non CHD compared with Pakistani non CHD, p** NPHSII CHD compared with Pakistani
CHD, LDL-C low density lipoprotein cholesterol, BMI body mass index
Continuous variables are expressed in mean ± standard deviation and categorical variables are expressed in numbers with percentage. P-value: the level of
statistical significance
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with the participants of NPHSII study from UK.. The
aim was to compare the allele frequencies and LDL-C
raising effect in two groups and to estimate the effect of
these SNPs on risk of developing CHD. Although many
studies have demonstrated a robust association of these
SNPs with LDL-C levels and CHD in different ethnici-
ties, the present study extends this to the subjects from
Pakistan.
The difference in allele frequency between European
and Asian subjects is not surprising and such differences
have been reported for other genes also [11, 14]. We
have also recently reported the difference in allele fre-
quencies of 19 CHD related loci between Pakstani and
UK people [27]. However, the effect on LDL-C will only
be of similar magnitude if either the SNP itself is func-
tional, or if non-functional, the SNP is in strong LD with
the functional SNP in both populations studied. The
similar effects on LDL-C observed here is compatible
with either of these possibilities. However, Pakistani
group also included females whereas in NPHSII, only
males were included. It has been reported that risk of
coronary events increases with increase in LDL-C in
postmenopausal females [28] and in females on hor-
mone replacement therapy [29]. The data on these pa-
rameters were not recordered for current study and if
included in future, it may provide valuable information.
The per allele effects of individual SNPs and gene
score on LDL-C did not differ significantly between UK
and Pakistani healthy subjects, however the R2 (propor-
tion of sample variance) values were considerably higher
in the Pakistani samples, indicating a better fit for the
models. The UK subjects showed greater variability in
Table 2 Mean ± SD LDL-C levels in 3 different genotypes of the SNPs studied
Gene SNP Genotype NPHSII non CHD NPHSII CHD Pakistani non CHD Pakistani CHD
SORT1 rs646776 GG 2.75 ± 1.00 2.93 ± 1.08 1.98 ± 0.31 2.42 ± 0.60
AG 2.95 ± 1.00 3.49 ± 0.86 2.11 ± 0.55 2.57 ± 0.79
AA 3.13 ± 1.01 3.34 ± 0.95 2.28 ± 0.34 2.88 ± 0.70
β(se) 0.18(0.04) 0.06(0.11) 0.15(0.04) 0.27(0.06)
R2 1.1 % 0.1 % 5.5 % 4.9 %
p-value 8.7x10-6 0.61 0.002 7.4 × 10-6
APOB rs1042031 AA 2.93 ± 0.99 2.40 ± 0 1.67 ± 0.12 2.02 ± 0.09
AG 2.98 ± 0.97 3.36 ± 0.89 2.10 ± 0.42 2.55 ± 0.39
GG 3.10 ± 1.03 3.36 ± 0.97 2.22 ± 0.44 2.78 ± 0.79
β (se) 0.11(0.04) 0.04(0.14) 0.15(0.06) 0.25(0.09)
R2 0.3 % 0.04 % 2.6 % 1.7 %
p-value 0.02 0.79 0.03 0.03
APOE rs429358 and rs7412 Ɛ2Ɛ2/Ɛ2Ɛ3/Ɛ2Ɛ4 2.67 ± 1.07 3.00 ± 0.86 1.97 ± 0.34 2.30 ± 0.47
Ɛ3Ɛ3 3.10 ± 0.98 3.39 ± 0.93 2.17 ± 0.45 2.69 ± 0.71
Ɛ3Ɛ4/Ɛ4Ɛ4 3.22 ± 0.99 3.45 ± 0.97 2.37 ± 0.35 3.07 ± 0.84
β(se) 0.26(0.04) 0.19(0.11) 0.20(0.06) 0.38(0.07)
R2 2.7 % 1.6 % 5.2 % 7.0 %
p-value 2.6×10-12 0.08 0.003 7.5 × 10-8
Ɛ3Ɛ3 vs. Ɛ4Ɛ4 β(se) 0.43(0.06) 0.39(0.21) 0.19(0.11) 0.39(0.14)
p-value 2.1×10-12 0.06 0.07 0.004
Ɛ3Ɛ3 vs. Ɛ2Ɛ2 β (se) -0.11(0.06) -0.07 (0.15) -0.20 (0.08) -0.38(0.09)
p-value 0.05 0.67 0.009 0.00004
β (se): beta effect which is increase or decrease (mmol/L) in LDL-C per risk allele along with standard error of mean. R2 = proportion of sample variance in LDL-C
Table 3 Mean gene score ± SD in NPHSII and Pakistani subjects
Gene score NPHSII samples Pakistani samples P* P**
Non CHD CHD p-value Non CHD CHD p-value
Unweighted. 4.26 ± 1.02 4.42 ± 0.98 0.05 4.28 ± 0.94 4.47 ± 0.91 0.02 0.77 0.52
Weighted 12.77 ± 7.99 14.17 ± 7.09 0.02 13.77 ± 6.19 14.5 ± 6.24 0.13 0.07 0.48
P* NPHSII non CHD compared with Pakistani non CHD, p** NPHSII CHD compared with Pakistani CHD
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LDL-C distribution with a standard deviation of 1.01
compared to 0.44 in the Pakistani controls, suggesting that
environmental factors may be having more influence in
this population, leading to a smaller proportion of the
variance being explained by the genetic component. The
non-genetic factors like high rate of urbanization, expos-
ure to tobacco smoke and industrial pollutants, alcohol in-
take and sedentary life style may be contributing to a
greater LDL-C variability in UK people.
The SNP, rs646776 is in complete LD with rs599839
which is a GWAS hit for LDL-C levels [25] and is asso-
ciated with the expression of CELSR2, PCSR2 and also
with SORT1 which is a gene located in an adjacent LD
block, encoding the protein sortilin. SORT1 expression
level is inversely proportional to the circulating levels of
ApoB and LDL-C [21]. A working hypothesis has been
proposed where by the protein sortilin binds both intra-
cellular apoB100 and extracellular LDL-C particles tar-
geting them for degradation in the lysosome [30]. The
minor allele ‘G’ is LDL-C lowering and hence CHD pro-
tective in both Pakistani and NPHSII which is in
agreement with previous studies [20, 31]. It is reported
that each minor allele is associated with 5-8 mg/dl re-
duction in LDL-C [32, 33]. Although the mean LDL-C
values (3.05 mmol/l) in NPHSII non CHD are higher
compared to Pakistani non-CHD (2.19 mmol/l), how-
ever, the percentage increase associated with this SNP is
not different in the two groups (6.65 % in NPHSII non
CHD, 7 % in Pakistani controls). It is evident from CHD
risk score calculators that 0.14 mmol/l increase in LDL-
C is expected to increase CHD risk by 9 %. So although
SNP rs599839 has been reported to be the functional
variant at this locus [32], the use of rs646776 as a proxy
appears to capture well the important variat at this
locus.
The effect of SNP rs1042031 appears to be counter in-
tuitive, as the minor allele ‘A’ is reported CHD risk allele
but is LDL-C lowering. In an early meta-analysis of pub-
lished studies [34], the minor allele was associated with
increased risk of CHD whereas, in our study it was
LDL-C lowering in both cohorts, which is in agreement
Table 4 Correlation of gene score with LDL-C in both groups
Gene score NPHSII non CHD NPHSII CHD Pakistani non CHD Pakistani CHD
Unweighted Correlation r = 0.19 r = 0.11 r = 0.37 r = 0.35
p-value 1.4 × 10-16 0.12 1.6× 10-8 4.1× 10-13
▫β(se) 0.19(0.02) 0.11(0.07) 0.17(0.03) 0.29(0.04)
R2 3.79 % 1.26 % 13.70 % 12.3 %
Weighted Correlation R = 0.23 r = 0.15 r = 0.33 r = 0.34
p-value 1.4x10-22 0.04 5.8 × 10-7 9.8x10-13
▪β(se) 0.22(0.02) 0.15(0.07) 0.18(0.03) 0.31(0.04)
R2 5.27 % 2.16 % 10.88 % 11.89 %
r the correlation coefficient, ▫β is the increase in LDL-C per risk allele of unweighted gene score, ▪β is the increase in LDL per SD of weighted gene score, R2 the
proportion of sample variance
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Fig. 1 The relation between gene score, frequencies and LDL-C in
the NPHSII. Along X-axis is unweighted gene score in NPHSII subjects;
along Y-axis on the left is the frequency of the subjects having a
specific gene score and right hand side Y-axis shows mean ± LDL-C in
a group of subjects with s a specific gene score value
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Fig. 2 The relation between gene score, frequencies and LDL-C in
Pakistani samples. The figure shows the relationship between gene
score, LDL-C and frequency of the individuals with a specific gene
score and mean ± SD LDL-C. It is clear that by increasing the gene
score value, the frequency of subjects with higher LDL-C levels
also increase
Shahid et al. Lipids in Health and Disease  (2016) 15:83 Page 6 of 9
with the results of a systematic review investigating vari-
ants in APOB and lipid levels although, this study found
no significant association between the rs1042031 and
CHD [35]. The major reported GWAS hit for LDL-C
levels in APOB is the miss sense variant rs1367117,
but there is very low LD (r2 = 0.01 in the 1000 Ge-
nomes pilot 1 CEU data) between this and rs1042031
[25]. The SNP rs1042031 is also in weak LD (r2 ~ 0.3
in the 1000 Genomes pilot 1 CEU data) with another
GWAS CHD hit rs515135, where the minor allele was
found to decrease CHD risk. For this SNP, the mech-
anism is unclear and is suggested that resulting amino
acid change alters the charge which may change the
tertiary structure of the protein and reduce the affinity
of the LDL-C particle for the LDL-receptor, although
no evidence has been published to support this hy-
pothesis so far. There also remains the possibility that
rs1042031 does not exert an effect itself, but is tagging
a functional SNP elsewhere in the APOB gene [36, 37].
The LD between SNPs in associated intervals and dif-
fering LD patterns among ethnicities suggests that
LDL-C and CHD may not have simple molecular basis
in the APOB gene [37].
For APOE it is clear that the variants used are them-
selves functional so any major difference in overall effect
size on LDL-C levels in UK and Pakistani subjects are
likely due to differences in APOE frequency. Human
apoE, acting as a ligand for LDL-receptor, has role in
clearance of VLDL remnants hence decreasing serum
total cholesterol [38–40]. It is estimated that inherited
factors explain about 60 % in determining the levels of
plasma total cholesterol and APOE polymorphisms con-
tribute 14 % among this genetically determined portion
[41]. The concentration of serum LDL-C in subjects
with different APOE genotypes is in the order of Ɛ2, Ɛ3
and Ɛ4 and the β effect was significantly higher in CHD
patients from the Pakistani population. The proportion
of sample variance R2 is also significant (p < 0.05), in
agreement with many other studies carried out in Asians
and Americans [4, 16, 42].
Since the effect of SNPs is additive and of modest
size, the problem was resolved by a strategy where their
effects were combined in a gene score. The similar gene
scores of healthy subjects from both populations, and a
significant difference in the mean gene score of non-
CHD and CHD subjects of both populations indicates
that the collective effect of the SNPs under study is
similar in both ancestries. The difference in gene score
is mainly driven by SORT1 and APOB but they have
low weighting, APOE has high weighting but the allele
frequencies were same between cases and controls. This
explains why for unweighted gene score there was a
significant different between cases and controls while
the weighted score was not.
Conclusion
In conclusion, the risk alleles of all the SNPs raised
LDL-C levels quantitatively in both UK and Pakistani
people. The effect size was similar in healthy people of
both populations but a bigger effect was observed in
Pakistani CHD subjects. The risk allele frequencies of all
the 4 SNPs studied were significantly different between
Pakistani and UK people and combined gene score of 4
SNPs was significantly associated with CHD risk in both
populations.
Limitations
Comparing the effects of SNPs on LDL-C in healthy
subjects from Pakistan and UK may be confounded by
different genetic backgrounds and environmental factors.
While the frequency of these SNPs was significantly dif-
ferent between the populations, the effect sizes of risk al-
leles on LDL-C were not, indicating that these concerns
are unfounded. There appears a larger variance in the
UK than in the Pakistaini subjects, such that the propor-
tion of sample variance explained by the SNPs was much
smaller in the UK sample, suggesting a greater hetero-
geneity, but whether this is genetic or environmental (or
both) cannot be resolved using these data. The Pakistani
cohort contained both males and females while the UK
group was only men, however, the frequency of these
autosomal SNPs should not be different in the two sexes,
and although effect sizes may be of different magnitude
in men and women, such differences are usually min-
imal. Also the sex heterogeneity in the allele frequencies
of the studied SNPs has not been reported in previous
meta analysis [25]. To confirm in more detail the rela-
tionship between these SNPs and CHD in Pakistan,
more studies with bigger sample size are required. As
each SNP has a small effect on the outcome, new SNPs
are required to be included, to construct a better fit
score for such multifactorial disease. The Pakistani
population, like the rest of the South Asian subcontinent
has, to date, been under represented in genetic studies
like Hap Map and 1000 genome projects. This study,
therefore adds new data to the field of the genetics of
LDL-C levels and CHD risk in this population.
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